Table 2.
Indications for esophagogastroduodenoscopy and diagnostic yield according to the American Society for Gastrointestinal Endoscopy guidelines n (%)
| ASGE Indication | Frequency | Relevant lesions (%) | P |
| Appropriate indication | 315 (82.7) | 36.6 | |
| Upper abdominal symptoms1 | 108 (28.3) | 21.3 | 0.001 |
| Esophageal reflux symptoms that are persistent or recurrent despite appropriate therapy | 46 (12.1) | 39.1 | 0.412 |
| Portal hypertension evaluation | 30 (7.9) | 80.0 | < 0.0001 |
| Follow-up of gastric ulcer | 24 (6.3) | 33.3 | 1.0 |
| Iron deficiency anemia | 23 (6.0) | 13.0 | 0.018 |
| Endoscopic treatment | 18 (4.7) | 77.8 | < 0.0001 |
| Dysphagia or odynophagia | 16 (4.1) | 62.5 | 0.027 |
| Surveillance for malignancy in patients with Barrett’s esophagus | 11 (2.9) | 90.9 | < 0.0001 |
| Persistent vomiting of unknown cause | 11 (2.9) | 18.2 | 0.346 |
| Active or recent GI bleeding | 10 (2.6) | 30.0 | 1.0 |
| For confirmation and specific histologic diagnosis of radiologically demonstrated lesions | 8 (2.1) | 50.0 | 0.451 |
| Sampling of tissue or fluid | 7 (1.8) | 14.3 | 0.236 |
| Others | 24 (6.2) | 25.0 | 0.523 |
| Uncertain indication | 22 (5.8) | 36.4 | |
| Anemia not otherwise characterized | 22 (5.8) | 36.4 | 1.0 |
| Inappropriate indication | 44 (11.5) | 11.4 | |
| Surveillance for malignancy in patients with chronic gastritis | 11 (2.9) | 0 | < 0.0001 |
| Surveillance for malignancy in patients with prior gastric operation | 10 (2.6) | 25.0 | 0.758 |
| Follow-up of duodenal ulcer | 8 (2.1) | 30.0 | 1.0 |
| Others | 15 (3.8) | 0 | < 0.0001 |
1
Upper abdominal symptoms persistent, despite therapy, associated with symptoms or signs suggesting serious organic disease or occurring in patients > 45 years old. ASGE: American Society for Gastrointestinal Endoscopy; GI: Gastrointestinal.